July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Xerox Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - XRX
December 08, 2024 14:24 ET | The Rosen Law Firm PA
NEW YORK, Dec. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Xerox Holdings Corporation (NASDAQ: XRX) between January 25,...
July 30, 2021 - ROSEN LOGO.jpg
רוזן, יועץ השקעות בכיר מהימן ומדורג, מעודד את משקיעי Xerox Holdings Corporation לקבל ייעוץ לפני תאריך יעד חשוב בתביעה ייצוגית בניירות ערך - XRX
December 08, 2024 14:24 ET | The Rosen Law Firm PA
ניו יורק, Dec. 08, 2024 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין (Rosen Law Firm), משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מזכיר לרוכשים את ניירות הערך של Xerox Holdings Corporation...
Merus logo 300dpi_.jpg
Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m
December 08, 2024 14:12 ET | Merus N.V.
Étude du pétosemtamab en association avec le pembrolizumab en 1re ligne de traitement dans le CETC r/m exprimant PD-L1 en cours, avec une actualisation des données cliniques prévue pour 2025 ...
BeamLogo_Color_CMYK.jpg
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
December 08, 2024 13:45 ET | Beam Therapeutics
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing...
July 30, 2021 - ROSEN LOGO.jpg
רוזן, יועץ השקעות מוביל, מעודד את משקיעי Unisys Corporation לברר לגבי חקירת תביעה ייצוגית בניירות ערך – UIS
December 08, 2024 13:39 ET | The Rosen Law Firm PA
ניו יורק, Dec. 08, 2024 (GLOBE NEWSWIRE) -- מדוע: משרד רוזן עורכי דין Rosen Law Firm, משרד עורכי דין בינלאומי העוסק בזכויות משקיעים, מודיע על חקירה של תביעות ניירות ערך פוטנציאליות בשם בעלי המניות...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, LEADING INVESTOR COUNSEL, Encourages Unisys Corporation Investors to Inquire About Securities Class Action Investigation – UIS
December 08, 2024 13:39 ET | The Rosen Law Firm PA
NEW YORK, Dec. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Unisys...
Agios_2021_Logo.png
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
December 08, 2024 12:40 ET | Agios Pharmaceuticals, Inc.
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...
JJ_Logo_SingleLine_Red_RGB.png
TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
December 08, 2024 12:35 ET | Janssen Cilag International NV
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. ...
roche-logo-blue.png
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
December 08, 2024 12:30 ET | F. Hoffmann-La Roche Ltd
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse...
C4Therapeutics-Website-Logo-FullColor-(R).png
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 08, 2024 12:30 ET | C4 Therapeutics, Inc.
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR);...